Experimental therapy in myelofibrosis with myeloid metaplasia
- 15 November 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 15 (12), 1555-1563
- https://doi.org/10.1517/13543784.15.12.1555
Abstract
Myelofibrosis with myeloid metaplasia (MMM) is a Philadelphia chromosome-negative myeloproliferative disorder that is characterised by constitutional symptoms, progressive anaemia and extramedullary haematopoiesis. There are no curative therapies available for patients with MMM apart from stem cell transplantation, which is associated with significant morbidity and mortality, and for which most patients are not suitable candidates. Traditional pharmacological therapy of MMM has focused on the palliation of symptoms associated with myeloproliferation and correction of cytopoenias. Recently, new findings regarding the molecular basis of MMM and the pathogenesis of the associated bone marrow stromal reaction have provided both basic and clinical researchers with invaluable tools to develop effective targeted therapies for patients with MMM. Several novel treatment strategies are being investigated including antiangiogenic agents, signal transduction inhibitors, inhibitors of fibrogenesis and small-molecule inhibitors of the JAK2V617F mutation. This article reviews the current status of experimental novel therapies for MMM.Keywords
This publication has 74 references indexed in Scilit:
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid MetaplasiaMayo Clinic Proceedings, 2004
- SU6668 in idiopathic myelofibrosis – A rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesisMedical Hypotheses, 2003
- Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in miceBlood, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Myelofibrosis with Myeloid MetaplasiaNew England Journal of Medicine, 2000
- Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosisBritish Journal of Haematology, 1997
- Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorNature, 1996